Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone510-748-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$444.94 million
Profitability
Miscellaneous
Employees2,200
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Penumbra (NYSE:PEN) Frequently Asked Questions
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra Inc (NYSE:PEN) posted its quarterly earnings data on Tuesday, August, 6th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.21 by $0.06. The firm had revenue of $134.20 million for the quarter, compared to the consensus estimate of $130.67 million. Penumbra had a return on equity of 6.80% and a net margin of 3.03%. The business's revenue for the quarter was up 22.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.15 earnings per share. View Penumbra's Earnings History.
When is Penumbra's next earnings date?
What guidance has Penumbra issued on next quarter's earnings?
Penumbra issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $535-540 million, compared to the consensus revenue estimate of $536.57 million.
What price target have analysts set for PEN?
8 brokers have issued 1 year target prices for Penumbra's shares. Their forecasts range from $152.00 to $185.00. On average, they expect Penumbra's stock price to reach $170.1667 in the next year. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Price Targets for Penumbra.
What is the consensus analysts' recommendation for Penumbra?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Penumbra.
Has Penumbra been receiving favorable news coverage?
Headlines about PEN stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Penumbra earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Penumbra.
Are investors shorting Penumbra?
Penumbra saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 4,637,700 shares, an increase of 8.8% from the July 31st total of 4,263,300 shares. Based on an average daily volume of 377,300 shares, the days-to-cover ratio is currently 12.3 days. Approximately 14.5% of the company's shares are short sold. View Penumbra's Current Options Chain.
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Nevro (NVRO).
What other stocks do shareholders of Penumbra own?
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
- Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
- Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
- Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
- Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)
Who are Penumbra's major shareholders?
Penumbra's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.01%), BlackRock Inc. (4.85%), BlackRock Inc. (4.85%), Thoroughbred Financial Services LLC (3.59%), Baillie Gifford & Co. (3.15%) and William Blair Investment Management LLC (2.76%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.
Which institutional investors are selling Penumbra stock?
PEN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Wells Fargo & Company MN, Vanguard Group Inc., Invesco Ltd., Janus Henderson Group PLC, Janus Henderson Group PLC, Waddell & Reed Financial Inc. and Bank of America Corp DE. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju and Thomas Wilder. View Insider Buying and Selling for Penumbra.
Which institutional investors are buying Penumbra stock?
PEN stock was bought by a variety of institutional investors in the last quarter, including Thoroughbred Financial Services LLC, William Blair Investment Management LLC, Ardevora Asset Management LLP, Baillie Gifford & Co., BlackRock Inc., BlackRock Inc., Nuveen Asset Management LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Penumbra.
How do I buy shares of Penumbra?
Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of PEN stock can currently be purchased for approximately $147.90.
How big of a company is Penumbra?
Penumbra has a market capitalization of $5.15 billion and generates $444.94 million in revenue each year. The company earns $6.60 million in net income (profit) each year or $0.51 on an earnings per share basis. Penumbra employs 2,200 workers across the globe.View Additional Information About Penumbra.
What is Penumbra's official website?
How can I contact Penumbra?
Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]
MarketBeat Community Rating for Penumbra (NYSE PEN)
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
